Yan Li

Prof. Yan Li


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
WXWei Xu
Wei Xu
YLYan Li
Yan Li
MJMei Ju
Mei Ju
WLWei Lai
Wei Lai
XLXueyan Lu
Xueyan Lu
LLLinfeng Li
Linfeng Li
Background. Glycyrrhizin is widely used in skin disorders, such as psoriasis, alopecia areata, and allergic diseases, but has not been extensively studied in patients with chronic eczema. Objective. To evaluate the efficacy and safety of oral compound glycyrrhizin (OCG) plus topical corticosteroid (TCS) in adults with chronic eczema. Methods. This was a multicenter, randomized, double‐blind, placebo‐controlled study in patients with chronic eczema (n = 199). Randomized participants from 6 centers in China received either 75 mg OCG capsules or placebo capsules three times a day and TCS (i.e., 0.1% mometasone furoate ointment) once a day for 28 days. Efficacy was determined by analyzing the mean change from the baseline using standardized measures including the Investigator’s Global Assessment (IGA) score, Eczema Area and Severity Index (EASI), and the visual analogue scale score (VAS) of itching. Results. Decreases in absolute EASI were significantly greater in the OCG‐treated group versus placebo on day 14 (−3.41 ± 1.41 vs. −2.71 ± 1.25, P < 0.001) and day 28 (−7.39 ± 1.71 vs. −6.64 ± 1.75, P = 0.003). OCG‐treated patients also saw greater benefit in other EASI metrics including EASI‐50 (96.8% vs. 87.9%, P = 0.021) and EASI‐75 (47.9% vs. 21.2%, P < 0.001) on day 28 compared with placebo. The absolute IGA score reductions were also significantly greater in the OCG group than the placebo (all P < 0.05). In addition, proportions of patients who achieve clear (0) IGA scores or almost clear (1) IGA scores were significantly higher in the treated group than placebo on day 14 (22.8% vs. 6.2%, P = 0.001) and day 28 (93.5% vs. 79.4%, P = 0.005). Moreover, the proportions of patients with reduced pruritus were significantly greater in the treated group than placebo on day 28 (94.7% vs. 83.8%, P = 0.016) and eczema recurrence was notably less in the OCG group versus placebo (3.19% vs. 12.12%, P = 0.021). Eleven patients experienced adverse events, but there was no significant difference in the proportion of patients affected (3.0% vs. 8.5%, P > 0.05). The most common adverse events were edema of both lower limbs. Conclusion. For adults with chronic eczema, OCG capsules combined with TCS is an effective and well‐tolerated treatment, suggesting that OCG may be a useful nonsteroidal agent with an additional effect for the treatment of chronic eczema by TCS.

22 February 2022 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
WQWenqiang Qi
Wenqiang Qi
YZYongheng Zhou
Yongheng Zhou
MZMinglei Zhong
Minglei Zhong
GLGuangda Lv
Guangda Lv
RLRongyang Li
Rongyang Li
QZQiujie Zhang
Qiujie Zhang

15 September 2019 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
YLYan Li
Yan Li
WXWei Xu
Wei Xu
JYJingyi Yao
Jingyi Yao
HCHaiyan Cheng
Haiyan Cheng
XSXiaoli Sun
Xiaoli Sun
LLLinfeng Li
Linfeng Li
Objectives. To investigate CD4+CD25+FoxP3+ T regulatory cells (Tregs) in the peripheral blood of patients with atopic dermatitis (AD) and its correlation with disease severity. Methods. Blood samples from 79 AD patients before and after four-week conventional treatment were collected. Cell counts of CD4+CD25+FoxP3+Tregs, CD4+CD25+FoxP3-T effector cells (Teffs), and CD4+IL-10+Tregs were analyzed by flow cytometry. Serum levels of IL-4, IL-10, IL-12, IL-13, IFN-γ, and TGF-β were measured by ELISA. Results. The pretreatment cell count of CD4+CD25+FoxP3+Tregs positively correlated with disease severity in all patients (P<0.0001). However, when that correlation was rechecked based on the treatment response, a much stronger correlation of that was found in those patients with remission after treatment, while no correlation of that was found in patients without remission. Both the cell count and proportions of peripheral CD4+CD25+FoxP3+Tregs and CD4+CD25+FoxP3-Teffs reduced significantly after treatment in patients with remission, but remained unchanged in patients without remission. The cell count and proportion of CD4+IL-10+Tregs did not change after treatment in both groups. In patients with remission, serum levels of IL-4 and IL-13 significantly reduced (all P<0.05); IL-12 and IFN-γ levels increased significantly (all P<0.05); IL-10 and TGF-β levels remained unchanged after treatment. None of those cytokine levels changed in patients without remission. Conclusions. CD4+CD25+FoxP3+Tregs is associated with AD development and severity in some patients but not in others. AD maybe divided into CD4+CD25+FoxP3+Treg-associated subtype, which CD4+CD25+FoxP3+Treg is parallel to the activity of AD, and nonassociated subtype, which CD4+CD25+FoxP3+Treg is not related. This subgroup difference may contribute partly to the nonidentical markers that have been found in AD and should be studied further.

23 April 2025 in Annals of Medicine
Verified
Journal Article
Open access
MLMing Li
Ming Li
LXLujing Xiang
Lujing Xiang
YLYan Li
Yan Li
Although compound glycyrrhizin (CG) has been widely used to alopecia areata (AA) in China, its efficacy and safety remain unclear. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of CG for AA. Eight literature databases were retrieved from their inceptions to 29 February 2024 to identify the eligible randomized controlled trials comparing CG plus conventional treatments with conventional treatments alone for the treatment of AA. Risk ratio (RR), mean difference and 95% confidence interval (CI) were used to estimate the pooled results. RevMan 5.4 (Cochrane Collaboration, Copenhagen, Denmark) and Stata 12.0 software (StataCorp., College Station, TX) were used for statistical analysis. A total of 23 eligible studies with 2219 patients were included. The pooled results revealed that CG plus conventional treatments was superior to conventional treatments alone in cure rate (RR = 1.60, 95%CI [1.47, 1.74], p < .001), total efficacy rate (RR = 1.37, 95%CI [1.29, 1.45], p < .001) and the Severity of Alopecia Tool (SALT) score, regardless of different conventional treatments, treatment courses and doses of CG. In terms of safety, a few patients suffered from adverse events (AEs), including oedema, elevated blood pressure and gastrointestinal tract discomfort, and the incidence of oedema was higher in the patients receiving CG (RR = 2.53, 95%CI [1.04, 6.19], p = .04). The combination of CG and conventional treatments was effective and safe for patients with AA, and CG could promote hair regrowth with mild AEs.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YLYan Li
Yan Li
MLMing Li
Ming Li
BZBoyang Zhou
Boyang Zhou
ZLZhou Liu
Zhou Liu
LLLinfeng Li
Linfeng Li
Objective. To evaluate the efficacy and safety of Qingpeng ointment for the treatment of subacute and chronic eczema. Method. Randomized controlled trials (RCTs) on Qingpeng ointment for subacute and chronic eczema were searched on PubMed, the Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure, Wanfang Database, Chinese Biomedical Literature Database, and Chinese Science and Technology Periodical Journal from their inception to 30 November 2020. Quality assessment and data analysis were performed by Review Manager 5.3. Results. A total of 26 RCTs were included. Qingpeng ointment could significantly improve the total efficacy rate (TER) (RR = 2.60, 95% CI: 2.11 to 3.21, P < 0.00001), reduce the total symptom score (TSS) (SMD = −2.35, 95% CI: ‐3.74 to ‐0.97, P = 0.0009), and decrease visual analogue scale (VAS) for pruritus (MD = −3.86, 95% CI: ‐4.41 to ‐3.31, P < 0.00001) compared with the placebo. The TER of Qingpeng ointment was similar to that of topical corticosteroid (TCS) (RR = 0.96, 95% CI: 0.88 to 1.03, P = 0.25), and the TSSs between Qingpeng ointment and medium or low potency TCS were not significantly different (SMD = −0.05, 95% CI: ‐0.22 to 0.12, P = 0.54). However, Qingpeng ointment was not superior to TCS in reducing VAS score (SMD = 0.48, 95% CI: 0.00 to 0.96, P = 0.05). In addition, Qingpeng ointment combined with TCS performed better than TCS alone in all three outcomes. For safety, nothing but skin irritative reactions occurred in the Qingpeng ointment group, and its incidence of skin irritative reactions was similar to those of the placebo (RR = 1.47, 95% CI: 0.61 to 3.55, P = 0.40) and TCS (RR = 1.82, 95% CI: 0.79 to 4.22, P = 0.16). The combined therapy did not increase the risk of skin irritative reactions (RR = 0.69, 95% CI: 0.27 to 1.78, P = 0.44). Conclusion. Qingpeng ointment is an effective and safe treatment for subacute and chronic eczema. It is also an add‐on treatment to TCS for eczema. However, due to the suboptimal quality of the included studies, more large‐sample and high‐quality RCTs are needed to improve the evidence quality.

1 March 2026 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
MJMeng Jiang
Meng Jiang
HCHaiyan Cheng
Haiyan Cheng
YLYan Li
Yan Li
HAHongmei Ai
Hongmei Ai
JLJun Li
Jun Li
WXWei Xu
Wei Xu
Background: Horizontal neck lines are an early and conspicuous marker of cutaneous aging. Intradermal hyaluronic acid (HA) injections have become a standard minimally invasive countermeasure, yet comparative data for composite HA solutions in Asian populations remain scarce. Purpose: To evaluate the efficacy and safety of injectable sodium hyaluronate composite solution (NCTF® 135 HA) compared with injectable sodium hyaluronate composite solution (HEARTY®) for the correction of moderate-to-severe neck wrinkles. Methods: In this prospective, multicenter, randomized, evaluator-blinded, active-controlled, non-inferiority trial, 188 subjects with moderate-to-severe neck wrinkles were randomly assigned (1:1) to the experimental group or the control group, with both groups receiving three sessions of non-cross-linked injectable sodium hyaluronate composite solution at 4-week intervals. Improvement of Allergan Transverse Neck Lines Scale (ATNLS), subject-assessed Global Aesthetic Improvement Scale (GAIS) and adverse events (AEs) were evaluated and compared before the 3 injection sessions and at 4, 12, and 24 weeks post-final injection. Results: At week 4 post-final injection, the ATNLS response rates were 88.30% in the experimental group and 85.11% in the control group, respectively, with a between-group difference of 3.19% (95% confidence interval (CI): [− 0.0723, 0.0987], p = 0.5410), demonstrating non-inferiority of the experimental treatment to the active control. Among the secondary endpoints, neither ATNLS response rates at additional time points nor subject-assessed GAIS responder rates showed statistically significant differences between groups. A total of 128 adverse events were reported, with no statistically significant difference between groups: 26 (27.66%) in the experimental group and 38 (40.43%) in the control group. No device- or procedure-related serious adverse events occurred. Conclusion: Injectable sodium hyaluronate composite solution (non-cross-linked) provides safe, effective, and non-inferior correction of moderate-to-severe neck wrinkles compared with active control, expanding minimally invasive therapeutic options for cervical rejuvenation.